# 摩根士丹利的David Bailey今日發布報告，維持對CSL的買入評級，目標價為166澳元。

*business · news · 2026-05-12 · Markets Insider*

## Key points

- 摩根士丹利的David Bailey維持對CSL的買入評級，目標價為166澳元。
- Morgans的Derek Jellinek同日也對CSL發出買入評級。
- 花旗昨日將CSL評級下調至持有，與近期的正面評級形成對比。
- CSL最新季度利潤從去年的20.1億澳元降至4.0837億澳元。

**Companies:** CSL, Morgan Stanley, Citi, Telix Pharmaceuticals, Ramsay Health Care, Cochlear
**Countries:** Australia, United States

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-csl-cmxhf-1036141671)

---

Canonical: https://newsio.io/zh-TW/n/42926e89-ce19-4785-ae1a-bb3c3a4bdd03/david-baileycsl166bailey49-042-72
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works